CRVO CervoMed Inc.

NASDAQ
$1.45

CervoMed Inc. (CRVO) is expected to report earnings on February 5, 2027, before the market open. The consensus earnings estimate is a loss of $0.46 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.3% since its last earnings release on November 6, 2026.

CervoMed Beat Consensus Estimates
Monday, November 9, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 5
Friday · Before Open
Earnings Whisper
-
vs ($0.46)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.76

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About CervoMed Inc.

CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase alpha. CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., is based in BOSTON.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.